DE69214656D1 - Therapeutisches verfahren zur behandlung von iddm - Google Patents

Therapeutisches verfahren zur behandlung von iddm

Info

Publication number
DE69214656D1
DE69214656D1 DE69214656T DE69214656T DE69214656D1 DE 69214656 D1 DE69214656 D1 DE 69214656D1 DE 69214656 T DE69214656 T DE 69214656T DE 69214656 T DE69214656 T DE 69214656T DE 69214656 D1 DE69214656 D1 DE 69214656D1
Authority
DE
Germany
Prior art keywords
alpha interferon
therapeutic method
neutralizing antibodies
antagonist
treating iddm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69214656T
Other languages
English (en)
Other versions
DE69214656T2 (de
Inventor
Timothy Stewart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE69214656D1 publication Critical patent/DE69214656D1/de
Publication of DE69214656T2 publication Critical patent/DE69214656T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69214656T 1991-08-30 1992-08-19 Therapeutisches verfahren zur behandlung von iddm Expired - Lifetime DE69214656T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75230991A 1991-08-30 1991-08-30
PCT/US1992/007094 WO1993004699A1 (en) 1991-08-30 1992-08-19 Therapeutic method for iddm

Publications (2)

Publication Number Publication Date
DE69214656D1 true DE69214656D1 (de) 1996-11-21
DE69214656T2 DE69214656T2 (de) 1997-03-13

Family

ID=25025756

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69214656T Expired - Lifetime DE69214656T2 (de) 1991-08-30 1992-08-19 Therapeutisches verfahren zur behandlung von iddm

Country Status (8)

Country Link
EP (1) EP0601052B1 (de)
JP (1) JPH06510061A (de)
AT (1) ATE144149T1 (de)
DE (1) DE69214656T2 (de)
DK (1) DK0601052T3 (de)
ES (1) ES2092698T3 (de)
GR (1) GR3022092T3 (de)
WO (1) WO1993004699A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7782894A (en) * 1993-09-17 1995-04-03 Laboratoire Europeen De Biotechnologie S.A. Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon
US7285526B2 (en) 1995-07-14 2007-10-23 Meiogen Biotechnology Corporation Interferon antagonists useful for the treatment of interferon related diseases
EP0859633A2 (de) * 1996-08-16 1998-08-26 Kurt B. Osther Behandlungsmethode für diabetis
AU761577C (en) 1997-12-08 2004-02-05 Genentech Inc. Human interferon-epsilon: a type I interferon
ZA9811070B (en) 1997-12-08 2000-07-03 Genentech Inc Type I interferons.
GB0001710D0 (en) * 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic treatment
DE60239522D1 (de) * 2001-01-09 2011-05-05 Baylor Res Inst Dallas Verfahren zur behandlung von autoimmunerkrankungen bei einem probanden und diagnostische in-vitro-assays
ES2313039T3 (es) 2003-04-23 2009-03-01 Medarex, Inc. Composiciones y procedimientos para la terapia de enfermedad inflamatoria intestinal.
WO2005059106A2 (en) 2003-12-10 2005-06-30 Medarex, Inc. Interferon alpha antibodies and their uses
RU2600884C2 (ru) 2004-06-21 2016-10-27 Е. Р. Сквибб энд Сонз, Эл,Эл.Си Антитела рецептора 1 интерферона альфа и их применение
JP5837730B2 (ja) 2005-02-10 2015-12-24 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗インターフェロンアルファモノクローナル抗体及び使用方法
US7888481B2 (en) 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
JP5208733B2 (ja) 2005-06-29 2013-06-12 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 組換えインターフェロンα２（ＩＦＮα２）変異体
RU2532832C2 (ru) 2008-05-07 2014-11-10 Аргос Терапьютикс, Инк. Гуманизированные антитела против альфа-интерферона человека
WO2019040674A1 (en) 2017-08-22 2019-02-28 Sanabio, Llc SOLUBLE INTERFERON RECEPTORS AND USES THEREOF

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335792C (en) * 1987-08-18 1995-06-06 Chaim O. Jacob Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
IL88377A (en) * 1988-11-14 1996-09-12 Yeda Res & Dev Cloning and expression of a protein which modulates cellular response to type I interferon

Also Published As

Publication number Publication date
ATE144149T1 (de) 1996-11-15
ES2092698T3 (es) 1996-12-01
EP0601052A1 (de) 1994-06-15
DE69214656T2 (de) 1997-03-13
GR3022092T3 (en) 1997-03-31
EP0601052B1 (de) 1996-10-16
DK0601052T3 (da) 1996-11-18
WO1993004699A1 (en) 1993-03-18
JPH06510061A (ja) 1994-11-10

Similar Documents

Publication Publication Date Title
DE69214656D1 (de) Therapeutisches verfahren zur behandlung von iddm
KR930702026A (ko) 자기항원의 경구 투여에 의한 자기면역 질병의 치료
SE8902638L (sv) Stabiliserade protein- eller peptidkonjugat
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
DE69830185D1 (de) Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen
BR9206398A (pt) Peptídio, processo para promover a liberação de níveis de hormônio de crescimento em um animal, composição farmacêutica, processos para promover a liberação e elevação de níveis de hormônio de crescimento no sangue, para tratar nanismo pituitário hipotalâmico, osteoporose ou queimaduras, para promover a cicatrização de feridas, a recuperação de cirurgias ou recuperação de doenças debilitantes agudas/crônicas, para prevenir ou reduzir caquexia em pacientes com câncer, para promover o anabolismo e/ou evitar catabolismo em seres humanos, para aumentar o músculo em um animal e/ou diminuir a gordura do corpo, para melhorar o padrão de lipídios no soro em seres humanos, e para preparar compostos
DK77090A (da) Immunmodulerende azaspiraner
DK641889D0 (da) Anvendelse af en blodpladeaktiveringsfaktorantagonist i kombination med monoklonale eller polyklonale antistoffer i et farmaceutisk praeparat til behandling af endotoksisk chok hos pattedyr
DK0527835T3 (da) Doseringsform til afgivelse af et anti-Parkinsonmiddel
DE3789082T2 (de) Expression eines tumorspezifischen Antigens eines rekombinanten Virusvektors sowie dessen Anwendung zur versorgenden oder heilenden Behandlung des entsprechenden Tumors.
DK0432400T3 (da) Farmakologisk aktiv forbindelse BPC, fremgangsmåde til fremstilling heraf og dens anvendelse indenfor terapien
JPH09504792A (ja) 慢性関節リウマチに関する治療
DE69307702T2 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
SE8804640D0 (sv) Medicament comprising cyclolinopeptide a
ATE111485T1 (de) Peptidbehandlung von hartnäckigen infektionskrankheiten.
Stuart et al. Failure of calcitonin to inhibit collagen-induced arthritis in rats
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
ES2038578T1 (es) Utilizacion de inmunoglobulinas g humanas, o de fragmentos fc de estas, como medicamento preparatorio para la administracion al hombre de anticuerpos monoclonales.
UA10254A (uk) Спосіб лікування цукрового діабету
RU93043512A (ru) Способ лечения крепитирующего тендовагенита предплечья
RU1821745C (en) Method for prognosticating effectiveness of efferent therapeutic treatment of patients suffering from immunocomplex diseases

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 601052

Country of ref document: EP